| Title: |
Pharmacogenomics [electronic resource] / Dan Roden. |
| Author(s)/Name(s): |
Roden, D. M. (Dan M.) |
| Publisher: |
[Bethesda, Md. : National Institutes of Health, 2008] |
| Related Names: |
National Institutes of Health (U.S.) |
| Series: |
OPASI rounds lecture series |
| Language: |
eng |
| Electronic Links: |
http://videocast.nih.gov/launch.asp?14234 |
| MeSH Subjects: |
Pharmacogenetics --trends |
|
Pharmaceutical Preparations |
|
Lectures |
| Summary: |
(CIT) Administration of virtually any drug to a group of patient’s results in a spectrum of responses: some patients may derive great benefit, in others there is no effect, and some patients will have adverse effects. The concept that such variability in drug response might include a heritable component goes back over 100 years. The identification of responsible variants in individual genes, and the sequencing of the human genome and its variants now opens the door to an era of personalized prescribing in which genomic information becomes a routine component of clinical decision-making. This talk will highlight current evidence linking genomic variants to variable drug responses, and will describe obstacles and their potential solutions to the implementation of such a personalized prescribing future. The Office of Portfolio Analysis and Strategic Initiatives (OPASI) provides the National Institutes of Health (NIH) and its constituent Institutes and Centers (ICs) with the methods and information necessary to manage their large and complex scientific portfolios, identifies in concert with multiple other inputs important areas of emerging scientific opportunities or rising public health challenges, and assists in the acceleration of investments in these areas, focusing on those involving multiple ICs. |
| Notes: |
Title from screen banner (viewed Feb. 29, 2008). |
|
Streaming video (1 hr., 25 min. : sd., col.). |
|
Mode of access: World Wide Web. |
|
Open-captioned. |
| NLM Unique ID: |
101465462 |
| Other ID Numbers: |
(DNLM)CIT:14234 |
